Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer
Clinical trial NCT03081234 · WITHDRAWN
Trial details
- NCT number
- NCT03081234
- Sponsor
- Novartis Pharmaceuticals
- Status
- WITHDRAWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-03-31
- Primary completion
- 2025-11-17
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.